Loss-of-function variants in the ELP1 gene are the most prevalent predisposing genetic factors in childhood medulloblastoma, accounting for about 30% of sonic hedgehog medulloblastoma (SHH-3 subtype).
Investigators from Anthem Biosciences Ltd. have published preclinical characterization data on their histone deacetylase (HDAC) inhibitor PAT-1102 for the potential treatment of cancer.
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer characterized by very poor prognosis and resistance to immunotherapy due to an immunosuppressive tumor microenvironment, which includes extensive desmoplasia and a dense stroma.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Hepatocellular carcinoma is the most frequent form of primary liver cancer, and most patients are diagnosed when the disease is already advanced and therefore prognosis is poor despite available treatments. Understanding what contributes to the malignancy may help develop effective treatments.
Gastric cancer, which is the fifth most frequent cancer globally and the third most frequent cause of cancer-related deaths, can be managed relatively well with existing therapies. Advanced gastric cancer, in contrast, is more difficult to manage.
Acute myeloid leukemia (AML) is the most prevalent hematological malignancy. Despite advances in the field, about 60% of patients with AML do not survive >5 years. It is an urgent need to identify novel therapeutic targets for managing AML.
Myosin Therapeutics Inc. has obtained IND clearance by the FDA for MT-125. A phase I study will evaluate MT-125 in combination with standard-of-care radiation in patients with newly diagnosed IDH wild type, MGMT unmethylated glioblastoma.
The EMA’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending European orphan drug designation for Hemispherian AS’s GLIX-1 for the treatment of glioma.
Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
